Hematologic Cancer Research at Providence Cancer Center
Developing new immunotherapies for blood-related cancers is the primary research focus of the Hematologic Malignancies Program at Providence Cancer Center. Many of our clinical trials are first-in-human studies of new immunotherapies aimed at maximizing the potential of the immune system to destroy tumors.
John Godwin, M.D., who leads the program, is a nationally known expert in leukemia and lymphoma and a member of the National Cancer Institute’s Leukemia Steering Committee. At Providence, Dr. Godwin is actively involved in both research and patient care. He initiates and leads groundbreaking research studies, and has been recognized as one of America’s top doctors by Castle Connolly.
Under Dr. Godwin’s leadership, our QOPI-certified team offers an extraordinary level of expertise in treating leukemia, myeloma, myelodysplastic syndrome, Hodgkin and non-Hodgkin lymphoma and other hematologic malignancies. The multidisciplinary team offers patient-focused care, expert second opinions for complex cases, and cutting-edge clinical and translational research trials of the most promising agents.
Currently, 20 clinical trials – of which most are immunotherapy studies – are open to patients with hematologic cancers. Here are four of them:
A Phase III, Randomized, Open-label, Clinical Trial to Compare Pembrolizumab With Brentuximab Vedotin in Subjects With Relapsed or Refractory Classical Hodgkin Lymphoma
Description: The purpose of this study is to evaluate pembrolizumab (MK-3475) in the treatment of participants with relapsed or refractory classical Hodgkin lymphoma. Participants will be randomized to receive either pembrolizumab or brentuximab vedotin for up to 35 three-week cycles of treatment.
A Phase I/ II Study to Evaluate the Safety and Preliminary Efficacy of Nivolumab in Combination With Brentuximab Vedotin in Subjects With Relapsed Refractory Non-Hodgkin Lymphomas With CD30 Expression (CheckMate 436: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 436)
Description: This is a signaling study to assess whether nivolumab in combination with brentuximab vedotin is safe and effective in certain subtypes of non-hodgkin lymphomas.
A phase I/II Study of vadastuximab talirine (SGN-CD33A) in combination with azacitidine in patients with previously untreated International Prognostic Scoring System (IPSS) Intermediate-2 or High risk myelodysplastic syndrome (MDS)
Description: This is a phase I/II study to evaluate the combination of vadastuximab talirine (SGN-CD33A; 33A) and azacitidine in subjects with previously untreated International Prognostic Scoring System (IPSS) intermediate-2 or high risk myelodysplastic syndrome (MDS).
A Phase 1, First in Human, Dose Escalation Study of MGD006, a CD123 x CD3 Dual Affinity Re-Targeting (DART®) Bi-Specific Antibody Based Molecule, in Patients With Relapsed or Refractory AML or Intermediate-2/High Risk MDS
Description: The primary goal of this Phase 1, dose-escalation study, is to determine the maximum tolerated dose level of MGD006 in patients with AML and MDS whose disease is not expected to benefit from cytotoxic chemotherapy. Studies will also be done to see how the drug acts in the body (pharmacokinetics, pharmacodynamics) and to evaluate potential anti-tumor activity of MGD006.
A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-C19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL)
Description: Study KTE-C19-102 is a phase 2, multicenter, open-label study evaluating the efficacy of KTE-C19 in subjects with Relapsed/Refractory MCL.
See all open studies for people with hematologic cancers ›
See all open studies in all cancer types ›